阿托伐他汀联合厄贝沙坦对早期糖尿病肾脏疾病患者血清VEGF的影响

The Effect of Atorvastatin Combine With Irbesartan on Serum VEGF in Patients With Early Diabetickidney Disease

目的探讨阿托伐他汀与厄贝沙坦联合使用对早期糖尿病肾脏疾病患者血清VEGF水平的影响。方法选择社区治疗的90例早期糖尿病肾脏疾病患者作为研究对象,随机分为观察组和对照组,各45例,对照组给予厄贝沙坦治疗,观察组给予阿托伐他汀联合厄贝沙坦治疗,观察比较两组患者的血清VEGF、Ccr(肌酐清除率)、TC(总胆固醇)、LDL-C(低密度脂蛋白胆固醇)、UAER(你到蛋白排泄率)、CRP(C反应蛋白)等指标。结果观察组患者TC、LDL-C、UAER、VEGF、CRP水平低于对照组,P<0.05,差异具有统计学意义。两组Ccr指标,P>0.05,差异不具有统计学意义。结论阿托伐他汀联合厄贝沙坦可有效降低早期糖尿病肾脏疾病患者VEGF水平,发挥保护肾脏作用。

Objective To investigate the therapeutic effects of atorvastatin statins and irbesartan combined effects on the serum level of VEGF in patients with diabetic kidney disease early. Methods Selected 90 cases with early diabetic kidney disease in community as the research object, randomly divided into observation group and control group, each group had 45 cases, the control group were treated with irbesartan treatment, the observation group were given atorvastatin statins combined with irbesartan in treatment, compared with the two groups of patients with serum VEGF, CCR （creatinine clearance）, TC （total cholesterol, LDL-C （low density lipoprotein cholesterol （HDL-C）, UAER （you to albumin excretion rate）, CRP （C-reactive protein） index. Results In the group of patients with TC, LDL-C, UAER, VEGF and CRP in observation was lower than that of the control group, P〈0.05, had difference statistically signiifcance. CCR index of the two groups, P〉0.05, had no difference statistically significance. Conclusion Atorvastatin statins combined with irbesartan can effectively reduce the VEGF level in early diabetic kidney disease patients, to play a renoprotective role.